Publication date: Jul 01, 2025
The protective component of specific memory B cells (MBCs) response relative to serum antibody response in primary SARS-CoV-2 infection is not well understood. Using a relatively unbiased B-cell culture method with a limited number of MBCs in each well (100 cells/well), we characterized the fine specificity of MBC responses against SARS-CoV-2 infection. While serum spike antibody is predominantly against S2 domain, the memory B cells mainly recognize S1 domain. The 44. 4-85. 3% of S-binding MBCs are specific to S1 domain. High frequency of MBCs (30-62% of SARS-CoV-2 S-specific MBCs) cross-reacting with SARS-CoV S has also been demonstrated. 22-33% of S1-binding MBCs were cross-reactive with the SARS-CoV RBD. In addition, a panel of human monoclonal Ab was derived from S1-binding MBCs recognizing six group epitopes (groups 1-6). Among them, RBD-specific Ab (826) in group 4 and cross-reactive Ab (808) could resist the neutralizing escape of omicron. Herein, we demonstrated that a dominant S1-directed MBC response was generated during primary SARS-CoV-2 infection. More importantly, the cross-reactive RBD-directed MBCs against SARS-CoV may protect against emerging SARS-CoV-2 variants.

Open Access PDF
| Concepts | Keywords |
|---|---|
| Antibody | Binding |
| Spike | Cov |
| Unbiased | Cross |
| Domain | |
| Dominant | |
| Infection | |
| Mbcs | |
| Memory | |
| Primary | |
| Rbd | |
| Reactive | |
| S1 | |
| Sars | |
| Serum | |
| Specific |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | IDO | cell |
| disease | MESH | SARS-CoV-2 infection |
| pathway | REACTOME | SARS-CoV-2 Infection |
| disease | MESH | infection |
| disease | IDO | process |
| disease | IDO | humoral immune response |
| disease | IDO | blood |
| disease | MESH | Infectious Diseases |
| disease | IDO | pathogen |
| drug | DRUGBANK | Coenzyme M |
| disease | MESH | breakthrough infections |
| disease | IDO | history |
| disease | IDO | protein |
| disease | IDO | assay |
| drug | DRUGBANK | Biotin |
| drug | DRUGBANK | Troleandomycin |
| disease | IDO | immunodeficiency |
| drug | DRUGBANK | Carboxymethylcellulose |
| drug | DRUGBANK | Isoflurane |
| disease | MESH | viral load |
| disease | MESH | virus infection |